首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Dialysis as a Treatment Option for a Patient With Normal Kidney Function and Familial Tumoral Calcinosis Due to a Compound Heterozygous FGF23 Mutation
【24h】

Dialysis as a Treatment Option for a Patient With Normal Kidney Function and Familial Tumoral Calcinosis Due to a Compound Heterozygous FGF23 Mutation

机译:由于化合物杂合FGF23突变,透析作为患有正常肾功能和家族性肿瘤辅病症的患者的治疗选择

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Primary tumoral calcinosis is a rare autosomal recessive disorder characterized by ectopic calcified tumoral masses. Mutations in 3 genes (GALNT3,FGF23, andKL) have been linked to this human disorder. We describe a case of a 28-year-old man with a history of painful firm masses over his right and left gluteal region, right clavicle region, knees, and left elbow. Biochemical analysis disclosed hyperphosphatemia (phosphate, 9.0 mg/dL) and normocalcemia (calcium, 4.8 mg/dL), with normal kidney function and fractional excretion of phosphate of 3%. Parathyroid hormone was suppressed (15 pg/mL), associated with a low-normal 25-hydroxyvitamin D (26 ng/mL) concentration but high 1,25-dihydroxyvitamin D concentration (92 pg/mL). Serum intact FGF-23 (fibroblast growth factor 23) was undetectable. Genetic analysis revealed tumoral calcinosis due to a compound heterozygous mutation inFGF23, c.201G>C (p.Gln67His) and c.466C>T (p.Gln156*). Due to lack of other treatment options and because the patient was facing severe vascular complications, we initiated a daily hemodialysis program even in the setting of normal kidney function. This unusual therapeutic option successful controlled hyperphosphatemia and reduced metastatic tumoral lesions. This is a report of a new mutation inFGF23in which dialysis was an effective treatment option for tumoral calcinosis with normal kidney function.
机译:原发性肿瘤钙化是一种稀有的常染色体隐性疾病,其特征在于异位钙化肿瘤肿块。 3基因(GalnT3,FGF23,ANDK1)的突变与该人类疾病有关。我们描述了一个28岁的男子,他的右臀部,右侧岩石地区,膝盖和左肘疼痛的群体历史。生物化学分析公开了高磷血症(磷酸盐,9.0mg / dL)和常规血症血症(钙,4.8mg / d1),肾功能正常,磷酸盐分数排泄3%。甲状旁腺激素被抑制(15pg / ml),与低正常的25-羟基vitamind(26ng / ml)浓度相关,但高1,25-二羟基维生素D浓度(92pg / ml)。血清完整的FGF-23(成纤维细胞生长因子23)是不可检测的。遗传分析显示出由于化合物杂合突变INFGF23,C.201G> C(P.GLN67His)和C.466C> T(P.Gln156 *)引起的肿瘤辅酶。由于缺乏其他治疗方案,并且由于患者面临严重的血管并发症,即使在正常的肾功能的设置中,我们也发起了每日血液透析计划。这种不寻常的治疗选择成功控制的高磷血症和降低的转移性肿瘤病变。这是一种新的突变Infgf23in,透析是具有正常肾功能的肿瘤辅病症的有效治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号